Additional Results From the ALLEVIATE-1 Phase 3 Trial in Patients Following Abdominoplasty Surgery (Businesswire) - Mar 6, 2025 - P3 | N=300 | ALLEVIATE1 (NCT06545097) | Sponsor: Tris Pharma, Inc | "Furthermore, results from the ALLEVIATE-1 clinical trial demonstrated that cebranopadol-treated patients also required significantly fewer doses of rescue medication than patients receiving placebo (LS mean difference of 2.2; p<0.001)."
P3 data • Pain
|